Patents Assigned to Montelino Therapeutics, Inc.
  • Patent number: 11981672
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: May 14, 2024
    Assignee: Montelino Therapeutics Inc.
    Inventors: Jenny Desantis, Roy Joseph Vaz, Michela Eleuteri
  • Patent number: 11787778
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: October 17, 2023
    Assignee: MONTELINO THERAPEUTICS, INC.
    Inventors: Jenny Desantis, Roy Joseph Vaz
  • Patent number: 11547759
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 10, 2023
    Assignee: MONTELINO THERAPEUTICS, INC.
    Inventors: Jenny Desantis, Roy Joseph Vaz
  • Patent number: 11098025
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitinization of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 24, 2021
    Assignee: Montelino Therapeutics, Inc.
    Inventors: Jenny Desantis, Roy Joseph Vaz